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OBJECTIVES: Compare pregnancy rates post-initiation of 84/7 (84 days levonorg-
estrel/ethinyl estradiol (EE) 0.15mg/0.03mg tablets plus EE 0.01mg or placebo for 7
days or 84 days levonorgestrel/ethinyl estradiol [EE] 0.1mg/0.02mg tablets plus EE
0.01mg for 7 days) to use of 21/7 (21 days combined EE/progestin plus 7 days pla-
cebo) or 24/4 (24 days EE/progestin plus 4 days placebo) oral contraceptive regimens
over the course of 1 year.METHODS:Data for this study were obtained from the US
i3 InvisionTM database from May 2009 through December 2011. Patients were in-
cluded if they received the medication of interest (first useindex date), were age
15-40 on index date, and had continuous insurance coverage from index date
through 1 year post index date. The 84/7 EE cohort was matched 2:1 without re-
placement to the 84/7 placebo cohort based upon age, sex, region, business type of
insurance, insurance product and year of index date. Differences in pregnancy
rates in the 1 year post index date were compared using a chi-square statistic.
RESULTS: There were 12,923 individuals in the 84/7 EE cohort and 1,276 individuals
in the 84/7 placebo cohort. Matching resulted in a final sample of 3,732 (2,488 in the
84/7 EE cohort and 1,244 in the 84/7 placebo cohort) for a successful match rate of
97.5%. Patients in the matched cohort had a mean age of 26.98 years (SD7.56),
resided predominantly in the South (55.55%) or Midwest (21.14%) and were most
commonly insured with point of service insurance (80.47%) or an exclusive pro-
vider organization (12.94%). Pregnancy rates in the 1 year post-initiation on an OC
were found to be statistically significantly lower for initiators of 84/7 EE compared
with 84/7 placebo (3.01% v 4.50%; P0.0200). CONCLUSIONS: Pregnancy rates were
significantly lower in women using a 84/7 EE OC regimen compared with a 84/7
placebo regimen.
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CONTRACEPTIVE UTILIZATION IN WOMEN WHO HAD AN ABORTION: A
CANADIAN COHORT-STUDY
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OBJECTIVES: Unintended pregnancies constitute a global problem associated with
substantial health care costs. In Canada, approximately 22% of all pregnancies will
lead to an abortion, with a higher rate (52%) in women under 20. As leading causes
of unintended pregnancies are closely related to the contraceptive method chosen,
the objective of this study was to analyze utilization of contraceptives in women
who had an abortion. METHODS: A retrospective cohort study was conducted us-
ing a random sample from the Régie de l’assurance-maladie du Québec (RAMQ)
prescriptions and medical services databases. Inclusion criteria were: women who
had an abortion at less than 14 weeks between January 1, 2008 and December 31,
2009 and who were continuously enrolled 12 months pre- and post-abortion.
Claims for contraceptives were analyzed in the year preceding and following the
abortion. RESULTS: Of the 7397 women included for analysis, 67.8% were between
15 and 29 years old. Approximately 30.2% filled at least one prescription for a
contraceptive in the year preceding the abortion; 82.9% of claims were oral contra-
ceptives. In the year after abortion, the usage of contraceptives increased to 54.3%.
Utilization of a long-acting reversible contraception (LARC) increased after abor-
tion. Levonorgestrel intrauterine system (IUS) was inserted on the day of the abor-
tion in 7.5% of women. Within one month of abortion, 47% of women claimed for
oral contraceptives, 27% for Levonorgestrel IUS, 12% for transdermal patches, 8%
for vaginal rings and 6% for depo-medroxyprogesterone acetate. CONCLUSIONS:
The data showed that the utilization of contraception increased after an abortion.
A valuable benefit of LARCs is that their effectiveness does not rely on continuous
user compliance, which could help explain the increased utilization of these meth-
ods after an abortion. However, the utilization of LARCs remains low which may
indicate an unmet need for a greater variety of LARC options.
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OBJECTIVES: Compare pregnancy rates post-initiation of 84/7 (84 days levonorg-
estrel/ethinyl estradiol (EE) 0.15mg/0.03mg tablets plus EE 0.01mg or placebo for 7
days or 84 days levonorgestrel/ethinyl estradiol [EE] 0.1mg/0.02mg tablets plus EE
0.01mg for 7 days) to use of 21/7 (21 days combined EE/progestin plus 7 days pla-
cebo) or 24/4 (24 days EE/progestin plus 4 days placebo) oral contraceptive regimens
over the course of 1 year.METHODS:Data for this study were obtained from the US
i3 InVisionTM database from January 1, 2006 through December 31, 2011. Patients
were included if they received the medication of interest (with first such receipt
identified as index date), were age 15-40 on index date, and had continuous insur-
ance coverage from index date through 1 year post index date. Two distinct anal-
yses were performed: 1 comparing pregnancy rates post-initiation on a 84/7 or 21/7
OC and the other comparing pregnancy post-initiation on a 84/7 or 24/4 OC. The
84/7 cohort was matched to each of the alternative cohorts of interest based upon
age, sex, region, business type of insurance, insurance product and year of index
date. RESULTS: There were 29,532 individuals in the 84/7 cohort, 662,721 individ-
uals in the 21/7 cohort, and 169,871 individuals in the 24/4 cohort. Matching of the
84/7 cohort to each of the alternative cohorts resulted in a successful match rate of
over 99% when comparing 84/7 with 21/7 and 96.7% when comparing 84/7 with
24/4. Pregnancy rates in the 1 year post-initiation on an OC were statistically sig-
nificantly lower for initiators of 84/7 compared with 21/7 (7.52% v 4.43%; P0.0001)
as well as when comparing 84/7 with 24/4 (6.95% v 4.43%; P0.0001).
CONCLUSIONS: In this study, pregnancy rates were significantly lower in women
using a 84/7 OC regimen compared with 21/7 or 24/4 regimens.
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OBJECTIVES: Insight into comorbidities and detailed drug exposure before and
during pregnancies as well as outcomes in children is pivotal to perform phar-
macoepidemiological pregnancy outcome studies. A database was constructed
that captures both detailed drug exposure before and during pregnancy as well as
pregnancy related information and outcomes of the neonate (and other relevant
clinical information) by linking the Netherlands Perinatal Registry (PRN) with the
PHARMO Record Linkage System (RLS). METHODS: The PRN is an anonymous na-
tionwide registry, including data from the midwifery, the obstetrics and the neo-
natology/pediatrics registry. The PHARMO RLS includes data from multiple health
care databases such as drug dispensings, hospitalizations, GP data and clinical
laboratory measurements and covers approximately 20% of the Dutch population.
Both databases were linked using different record linkage techniques. Key vari-
ables (e.g. maternal age, gestational duration, parity, singleton birth) were assessed
to determine comparability between the PRN and the linked PRN-PHARMO RLS
pregnancies. RESULTS: The linkage of 1,453,504 pregnancies registered between
2000 and 2007 in the PRN with PHARMO RLS resulted in a cohort of 151,250 women
with complete drug and clinical data available for 203,972 pregnancies. Linked
pregnancies were comparable with all pregnancies. In 67% of all pregnancies at
least one prescription drug was used. The most frequently used drugs included
anti-anemic preparations (26%), antibacterials (20%) and gynecologic anti-infec-
tives (14%). As dispensing date, duration of use and dose are recorded in the
PHARMO RLS, exposure per trimester can be assessed and related to birth out-
comes, such as prematurity and congenital defects as recorded in the PRN.
CONCLUSIONS: Linkage of the Netherlands Perinatal Registry and the PHARMO
RLS creates the possibility to study detailed drug utilization and comorbidities of
mothers before, during and after pregnancy and of children. This enables to study
potential adverse effects that might impact pregnancies or child development later
in life.
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OBJECTIVES: Formulary system of medical provision is created in Ukraine.. The
Order of MOH of Ukraine No 529 “About Creation of Formulary System for Health
Institutions” was approved in 2009. The Fourth edition of State Formulary ap-
proved in 2012. METHODS: We used comparative analysis of drug information for
children from all editions of the State Formylary (2009-2012) were conducted.The
State Formylary contains a special section for children Neonatology medicines.
All medicines in this section are classified into 11 pharmacological groups.
RESULTS: In 2009 were included 95 medicines for children, 2010 – 91, 2011 – 81, 2012
- 78 respectively. For the first time in 2011 the State Formylary were included three
preparations for replacement surfactant therapy for newborns with respiratory
disorders. It’s Ukrainian-made preparation Neosurf emulsion, and two imported
medicines Infasurf suspension, and Curosurf suspension. We evaluated the
costs of treatment were 223.2 € (1€  9.98 UAH), 404.5 €, 630.6 € respectively. Since
2007 for the state budget were purchased Curosurf, from 2008 - Neosurf, and 2011
- Infasurf. We found regional differences concerning the financing of these medi-
cines. Curosurf funded by 11% of needs in Dnipropetrovsk, Donetsk regions, 10% -
in Kharkiv region, 8% - in Lviv region, less than 5% - all other 23 Ukraine regions.
CONCLUSIONS: The results showed that in the State Formylary 2009-2012 the
number of medicines for children was decreased by 22%. The costs of treatment
surfactant is high enough.It is established that the highest compensation surfac-
tants were in the Crimea, Donetsk, Dnipropetrovsk, Lviv regions. Is grounded that
is necessary the creation special Ukranian Formylary for children, which will in-
clude a larger number of children’s medicines.
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OBJECTIVES: With the widespread of second-generation antipsychotics (SGAs)
used among children and adolescents, the treatment effectiveness has been of
great interest alongside with the efficacy and safety in this population. The study
was designed to assess whether SGAs are associated with reduced service uses and
service costs in the real world. Factors associated with health service costs were
also examined. METHODS: The claim data (PIMC) of 1996-2008 from the National
Insurance Plan of Taiwan was used. Patients aged less than 20 with an incident use
of antipsychotics and last for over 12 months during this period were included for
analysis. Comparisons were made between 8 SGAs and 2 first-generation antipsy-
chotics (FGAs). Changes in service uses and service costs (all-cause, psychiatric
service, non-psychiatric service costs, and medication costs) were compared.
Mann-Whitney U tests and 95% confidence interval were used to examine differ-
ences. Multivariate regressions with propensity scores adjustment were performed
to explore factors associated with psychiatric service costs. RESULTS:A total of 343
encounters were included and results showed reduced psychiatric service uses in
SGAs group, but not psychiatric services costs in the SGAs group. Antipsychotics
costs were nearly 6-fold higher in the SGAs group, but the antiparkinsonian med-
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ication costs were not statistically different between two groups. Factor positively
associated with service costs included excess filler (RR7.9, p0.0002), relapse
event (RR4.0, p0.0001) and adverse event like EPS (RR1.6, p0.008), while types
of antipsychotics and diagnoses were not significant factors after adjusting for
covariates. CONCLUSIONS: SGAs were associated with reduced psychiatric service
uses as compared to FGAs within the 12-month treatment period; however, service
costs were not different and medication costs were significantly higher in the SGAs
group. Excess fillers, relapse and incidence of EPS were factors of high costs among
children and adolescents psychiatric patients treated with antipsychotics in Tai-
wan.
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OBJECTIVES: In developed countries, rotavirus disease causes significant burden,
both on health care systems and society. Two effective and well-tolerated rotavirus
vaccines were marketed in Europe & USA in 2006. Since then, there have been
significant discrepancies in policy decisions and health technology assessments
(HTAs) relating to the inclusion of universal vaccination into national immunisa-
tion programmes, thereby causing unequal population access to rotavirus vacci-
nation. This study aims to understand past HTAs and policy decisions concerning
the recommendation, funding and implementation of universal rotavirus vaccina-
tion in developed countries. METHODS: A comprehensive literature search and
critical appraisal of rotavirus HTAs, statements and policy decisions was per-
formed in 20 developed countries (17 Western European countries, USA, Canada
and Australia). RESULTS: Rotavirus HTAs/statements have been issued in 15 out of
20 countries included in this study. At mid-June 2012, 8 countries have imple-
mented rotavirus vaccination programmes; 2 countries have not recommended
vaccination; 2 countries have recommended and funding processes are ongoing. In
all other countries, the rotavirus decision-making process has not started or is
underway. Despite significant differences in HTA criteria, methods and processes
across countries, there is consistency in the key parameters impacting policy de-
cisions: burden of disease, economic evaluation, vaccine efficacy and safety. Posi-
tive or negative outcomes largely depend on varying interpretations of similar
evidence. For example, several National Immunisation Technical Advisory Groups
and policy makers considered evidence pertaining to rotavirus disease burden
(morbidity) as significant enough to justify its inclusion in the national immunisa-
tion programme, whereas others considered it as insufficient since rotavirus mor-
tality is low. CONCLUSIONS: This study highlights the need for a common decision
analytic framework to foster structured and transparent HTAs and improved de-
cision-making processes, with the ultimate aim of enhancing future European pop-
ulation access to rotavirus vaccination.
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OBJECTIVES: Five years ago the United States government passed the Food and
Drug Administration Amendments Act of 2007 (FDAAA) expanding the FDA’s au-
thority to require post-marketing studies. Prior to this, pregnancy registries, a valu-
able tool for studying the teratogenicity of newly marketed drugs, were primarily
voluntary efforts. Both the FDA (2002) and EMA (2005) issued guidance on post-
marketing studies during pregnancy. The objectives of this research were to eval-
uate the impact of FDAAA on childbearing populations and trends in post-market-
ing commitments/requirements (PMC/Rs). METHODS: Publicly available FDA
databases were analyzed to identify all new molecular entities approved between
January 2008 and May 2012 and associated PMC/Rs and REMS related to pregnancy/
lactation in humans. Data was augmented from the FDA’s list of pregnancy regis-
tries and assigned pregnancy drug category. RESULTS:Over the 4.5 year period, the
FDA approved 125 new compounds (100 drugs, 25 biologics). Overall 78% had at
least one PMC/R (79% of drugs, 84% of biologics). The proportion of new drugs with
a pregnancy related PMC/R was 9% overall and increased over time from 5% in 2008
to a peak of 19% in 2010 before declining to 4% in 2011. Pregnancy categories were
B (26), C (70), D (17), X (12). Of the 57 pregnancy registries listed on the FDA’s website,
13 are associated with drugs approved during the time period under study however
only 6 of these were PMC/R and all were for category C compounds. A single cate-
gory X drug had a pregnancy/lactation related PMC/R.CONCLUSIONS:The majority
of pregnancy registries are for medicines with FDA assigned pregnancy category C.
Category X drugs are not more likely to have REMS or PMC/Rs despite their known
potential for reproductive harm. Population characteristics such as gender, age,
and indication for the prescription are powerful indicators of when PMC/Rs are
necessary.
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OBJECTIVES: Pediatric Investigation Plans (PIPs) were introduced by the European
Commission in January 2007 to help ensure that medicines for children are in-
cluded in the mainstream drug development process in Europe. The objective of
this study was to review all authorized products by the European Medicines Agency
(EMA) from 1995 to 2011 to identify (1) products with a potential pediatric indica-
tion, and (2) products with a PIP application. METHODS: On the EMA website, the
European Public Assessment Reports (EPARs) were searched manually. For each
product, the Summary of Product Characteristics (SmPC) was reviewed to explore
quotes relative to any potential pediatric indication. The products were distributed
in four categories: C1adult indication only; C2safety/efficacy not studied in chil-
dren; C3adult and pediatric indication; and C4pediatric indication only. For
each product, the EMA pediatrics database was searched for PIP applications.
RESULTS:A total of 633 products were authorized by the EMA (281 in 1995-2006 and
352 in 2007-2011). From 1995 to 2006, 33.53% of the authorized products presented
a lack of evidence in the pediatric population as did 57% in the period of 2007-2011.
In total, 746 PIP applications were identified (products authorized and under devel-
opment). A PIP was requested for 21.4% of the products authorized before the
regulation (1995-2006) and for 19% of the products authorized after the EU pediatric
regulation. CONCLUSIONS: The categorization of authorized products according to
the SmPC quotes showed that many products had potential pediatric indications
needing confirmation through new research programs. As expected, most of the
PIP applications concern products under development. However, it is interesting to
note that 20% of the requests concern authorized products, with a higher percent-
age of requests for products authorized before the regulation. These findings sug-
gest that the pediatric regulation in Europe is fostering research to create more
therapeutic options for children.
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OBJECTIVES: There is a lack of long-term data from the real-life setting to docu-
ment the clinical evolution of Alzheimer’s disease (AD) patients, especially in mod-
erate AD where disease management becomes more complex. The EVOCOST study
aims to describe how moderate AD is associated with a relevant disease-related
disability progression and an increase in caregiver burden. METHODS: The EVO-
COST study is a prospective 12-month multicentre cohort study recruiting com-
munity-dwelling moderate AD patients in Spain. Visits were scheduled at baseline,
6 and 12 months according to routine clinical practice. Data on socio-demographic
characteristics, disease history and comorbidities were collected at baseline. Clin-
ical evolution and caregiver burden were measured using the following assess-
ment tools: Global Deterioration Scale (GDS) for severity, Mini-Mental State Exam-
ination (MMSE) for cognition, Clinical Global Impression (CGI) for global status,
Basic and Instrumental Activities of Daily Living (BADL and IADL) for functional
disability, brief Neuropsychiatric Inventory (NPI-Q) for behaviour, Zarit Burden In-
terview (ZBI) and time spent on care for caregiver burden. Changes from baseline
were calculated and tested with Wilcoxon signed rank tests. RESULTS: A total of
209 patients were included at baseline, 76.1% of them were women, with a mean
age of 78.4 years and a mean MMSE of 15.2. At the 12-month visit, data were
available on 174 patients (patient’s attrition rate 16.8%). Clinical symptoms wors-
ened significantly during the 12-month study follow-up in terms of severity
(	GDS0.5, p0.001), cognition (	MMSE-2.9, p0.001), global status
(	CGI0.3, p0.001), and function (	BADL-1.7, p0.001; 	IADL-1.2, p0.001).
No significant change was observed on behaviour (	NPI severity0.5, p0.325;
	NPI distress0.4, p0.375). Caregiver burden also worsened significantly
(	ZBI2.5, p0.002; 	time spent on care56hours per month, p0.001).
CONCLUSIONS: The EVOCOST study illustrates well the patient clinical worsening
and the increase in caregiver’s burden associated with management of moderate
AD.
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OBJECTIVES: To assess clinical effectiveness of cognitive behavioural therapy
(CBT) in patients with multiple sclerosis (MS) fatigue. METHODS: Embase® and
Cochrane databases were searched up to June 2012 to identify randomised con-
trolled trials published in English evaluating effect of CBT (disseminated by any
mode) in patients with MS fatigue. Eligibility of trials was assessed by two review-
ers with any discrepancy reconciled by a third, independent reviewer. To compare
CBT with other therapies, random-effect meta-analysis was conducted using
Stata® (v11.1) on change from baseline to endpoint in fatigue score. RESULTS: Four
studies of 107 retrieved citations met pre-defined inclusion criteria. Two studies
compared CBT to no therapy and one study each compared CBT to relaxation
therapy (RT) and supportive-expressive group therapy (SEGP). All studies were well
conducted and no significant differences were observed between treatment groups
for demographic characteristics. Weighted mean difference (WMD) demonstrated
statistically significant reduction for change in fatigue score at 2 months from
baseline with CBT versus no therapy (-7.04; p0.001). When CBT was compared to
RT, WMD was -4.29 (p0.001) at 2 months, -2.74 (p0.013) at 5 months, and -2.74
(p0.027) at 8 months indicating that CBT group improved significantly on fatigue
than RT group and this improvement was sustained over a period of time. Further,
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